{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T01:10:58Z","timestamp":1793149858308,"version":"4.5.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mycopathologia"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Despite important advancements in diagnostic modalities, routine use of therapeutic drug monitoring (TDM) and newer antifungal therapies, there is a paucity of contemporary data regarding clinical characteristics and outcomes of invasive aspergillosis (IA) in the United States.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Single-center, retrospective cohort study of hospitalized patients between 2015 and 2020, who had active hematological malignancy (HM) or had undergone transplantation and cellular therapy (TCT) and had probable\u00a0or\u00a0proven IA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Sixty-two patients with probable\u00a0or\u00a0proven IA, including 21 HM and 41 TCT, were identified. Forty-four percent of the cases corresponded to breakthrough IA. Bronchoalveolar lavage galactomannan was\u2009\u2265\u20091 in 71% and\u2009\u2265\u20090.5 in 88%, while serum galactomannan was\u2009\u2265\u20090.5 in only 34%. Among assessable patients (n\u2009=\u200959), 90-day partial or complete response to antifungal therapy occurred in 39%. All-cause mortality for the entire cohort was 22% at 30\u00a0days and 46% at 90\u00a0days. IA attributable mortality was 18% at 30\u00a0days and 38% at 90\u00a0days. Achieving therapeutic antifungal serum levels was associated with a reduction in all-cause mortality, while prior clinically significant CMV infection (aOR 9.65, 95% CI 1.34\u201369.6;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.025) and relapsed\/refractory hematological disease (aOR 8.5, 95% CI 2.23, 32.4;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.002) were associated with higher IA attributable mortality.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Despite advancements in diagnosis and treatment, IA remains associated with poor outcomes in hematological patients in the contemporary era. Newer antifungals and improved strategies for monitoring and prevention of IA in these vulnerable patient populations are urgently needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11046-025-01046-1","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T13:57:55Z","timestamp":1770299875000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Clinical Characteristics and Outcomes of Invasive Aspergillosis in Patients with Hematological Malignancies and Transplantation and Cellular Therapies in the Contemporary Era"],"prefix":"10.1007","volume":"191","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-8162-7843","authenticated-orcid":false,"given":"Christopher M.","family":"Lopez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6125-830X","authenticated-orcid":false,"given":"Jose F.","family":"Suarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A.","family":"Mendoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2765-582X","authenticated-orcid":false,"given":"Anthony D.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2298-7829","authenticated-orcid":false,"given":"Jill","family":"Lykon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2710-7652","authenticated-orcid":false,"given":"Wenhui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4479-8726","authenticated-orcid":false,"given":"Michele I.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4938-125X","authenticated-orcid":false,"given":"Yoichiro","family":"Natori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4324-5748","authenticated-orcid":false,"given":"Mohammed","family":"Raja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lazaros J.","family":"Lekakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1661-5865","authenticated-orcid":false,"given":"Amer","family":"Beitinjaneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2817-6836","authenticated-orcid":false,"given":"Antonio","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5685-7204","authenticated-orcid":false,"given":"Trent P.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6491-0044","authenticated-orcid":false,"given":"Jay","family":"Spiegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noa G.","family":"Holtzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1992-7899","authenticated-orcid":false,"given":"Denise","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna V.","family":"Komanduri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose F.","family":"Camargo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"issue":"8","key":"1046_CR1","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1086\/651263","volume":"50","author":"DP Kontoyiannis","year":"2010","unstructured":"Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) database. Clin Infect Dis. 2010;50(8):1091\u2013100. https:\/\/doi.org\/10.1086\/651263.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"1046_CR2","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1086\/595846","volume":"48","author":"D Neofytos","year":"2009","unstructured":"Neofytos D, Horn D, Anaissie E, et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis. 2009;48(3):265\u201373. https:\/\/doi.org\/10.1086\/595846.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"1046_CR3","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1086\/522189","volume":"45","author":"L Pagano","year":"2007","unstructured":"Pagano L, Caira M, Nosari A, et al. Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study--Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clin Infect Dis. 2007;45(9):1161\u201370. https:\/\/doi.org\/10.1086\/522189.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"1046_CR4","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.jtct.2020.10.003","volume":"27","author":"SS Dadwal","year":"2021","unstructured":"Dadwal SS, Hohl TM, Fisher CE, et al. American Society of Transplantation and Cellular Therapy Series, 2: management and prevention of aspergillosis in hematopoietic cell transplantation recipients. Transplant Cell Ther. 2021;27(3):201\u201311. https:\/\/doi.org\/10.1016\/j.jtct.2020.10.003.","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"1046_CR5","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/j.1600-0609.2008.01096.x","volume":"81","author":"M Caira","year":"2008","unstructured":"Caira M, Girmenia C, Fadda RM, et al. Invasive fungal infections in patients with acute myeloid leukemia and in those submitted to allogeneic hemopoietic stem cell transplant: Who is at highest risk? Eur J Haematol. 2008;81(3):242\u20133. https:\/\/doi.org\/10.1111\/j.1600-0609.2008.01096.x.","journal-title":"Eur J Haematol"},{"key":"1046_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/jof7080588","author":"MD Bergamasco","year":"2021","unstructured":"Bergamasco MD, Pereira CAP, Arrais-Rodrigues C, et al. Epidemiology of invasive fungal diseases in patients with hematologic malignancies and hematopoietic cell transplantation recipients managed with an antifungal diagnostic driven approach. J Fungi. 2021. https:\/\/doi.org\/10.3390\/jof7080588.","journal-title":"J Fungi"},{"key":"1046_CR7","doi-asserted-by":"publisher","first-page":"805514","DOI":"10.3389\/fcimb.2021.805514","volume":"11","author":"A Busca","year":"2021","unstructured":"Busca A, Cinatti N, Gill J, et al. Management of invasive fungal infections in patients undergoing allogeneic hematopoietic stem cell transplantation: the Turin experience. Front Cell Infect Microbiol. 2021;11:805514. https:\/\/doi.org\/10.3389\/fcimb.2021.805514.","journal-title":"Front Cell Infect Microbiol"},{"issue":"4","key":"1046_CR8","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1093\/cid\/ciu337","volume":"59","author":"JF Camargo","year":"2014","unstructured":"Camargo JF, Husain S. Immune correlates of protection in human invasive aspergillosis. Clin Infect Dis. 2014;59(4):569\u201377. https:\/\/doi.org\/10.1093\/cid\/ciu337.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"1046_CR9","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S1473-3099(09)70019-2","volume":"9","author":"C Mengoli","year":"2009","unstructured":"Mengoli C, Cruciani M, Barnes RA, Loeffler J, Donnelly JP. Use of PCR for diagnosis of invasive aspergillosis: systematic review and meta-analysis. Lancet Infect Dis. 2009;9(2):89\u201396. https:\/\/doi.org\/10.1016\/S1473-3099(09)70019-2.","journal-title":"Lancet Infect Dis"},{"issue":"10020","key":"1046_CR10","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","volume":"387","author":"JA Maertens","year":"2016","unstructured":"Maertens JA, Raad II, Marr KA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016;387(10020):760\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(15)01159-9.","journal-title":"Lancet"},{"issue":"10273","key":"1046_CR11","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S0140-6736(21)00219-1","volume":"397","author":"JA Maertens","year":"2021","unstructured":"Maertens JA, Rahav G, Lee DG, et al. Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial. Lancet. 2021;397(10273):499\u2013509. https:\/\/doi.org\/10.1016\/S0140-6736(21)00219-1.","journal-title":"Lancet"},{"issue":"1","key":"1046_CR12","doi-asserted-by":"publisher","first-page":"3379","DOI":"10.1038\/s41598-025-87605-4","volume":"15","author":"F Liu","year":"2025","unstructured":"Liu F, Chen W, Qi H, et al. Clinical characteristics and prognosis of patients treated as invasive pulmonary aspergillosis outside of severe immunosuppression. Sci Rep. 2025;15(1):3379. https:\/\/doi.org\/10.1038\/s41598-025-87605-4.","journal-title":"Sci Rep"},{"key":"1046_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/jof7121092","author":"A Goyeneche-Garcia","year":"2021","unstructured":"Goyeneche-Garcia A, Rodriguez-Oyuela J, Sanchez G, Firacative C. Clinical and epidemiological profile of patients with invasive aspergillosis from a fourth level hospital in Bogota, Colombia: a retrospective study. J Fungi. 2021. https:\/\/doi.org\/10.3390\/jof7121092.","journal-title":"J Fungi"},{"key":"1046_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/jof8040344","author":"P Soontrapa","year":"2022","unstructured":"Soontrapa P, Chongtrakool P, Chayakulkeeree M. Characteristics and outcomes of patients with invasive pulmonary aspergillosis and respiratory tract Aspergillus colonization from a tertiary university hospital in Thailand. J Fungi. 2022. https:\/\/doi.org\/10.3390\/jof8040344.","journal-title":"J Fungi"},{"key":"1046_CR15","doi-asserted-by":"publisher","first-page":"756237","DOI":"10.3389\/fmed.2021.756237","volume":"8","author":"X Tong","year":"2021","unstructured":"Tong X, Liu T, Jiang K, et al. Clinical characteristics and prognostic risk factors of patients with proven invasive pulmonary aspergillosis: a single-institution retrospective study. Front Med. 2021;8:756237. https:\/\/doi.org\/10.3389\/fmed.2021.756237.","journal-title":"Front Med"},{"issue":"12","key":"1046_CR16","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1086\/588660","volume":"46","author":"B De Pauw","year":"2008","unstructured":"De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group. Clin Infect Dis. 2008;46(12):1813\u201321. https:\/\/doi.org\/10.1086\/588660.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"1046_CR17","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","volume":"71","author":"JP Donnelly","year":"2020","unstructured":"Donnelly JP, Chen SC, Kauffman CA, et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2020;71(6):1367\u201376. https:\/\/doi.org\/10.1093\/cid\/ciz1008.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"1046_CR18","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.1093\/cid\/ciaa1855","volume":"72","author":"BD Alexander","year":"2021","unstructured":"Alexander BD, Lamoth F, Heussel CP, et al. Guidance on imaging for invasive pulmonary aspergillosis and mucormycosis: from the Imaging Working Group for the Revision and Update of the Consensus Definitions of Fungal Disease from the EORTC\/MSGERC. Clin Infect Dis. 2021;72(2):S79\u201388. https:\/\/doi.org\/10.1093\/cid\/ciaa1855.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"1046_CR19","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1111\/myc.12960","volume":"62","author":"OA Cornely","year":"2019","unstructured":"Cornely OA, Hoenigl M, Lass-Florl C, et al. Defining breakthrough invasive fungal infection-position paper of the mycoses study group education and research consortium and the European Confederation of Medical Mycology. Mycoses. 2019;62(9):716\u201329. https:\/\/doi.org\/10.1111\/myc.12960.","journal-title":"Mycoses"},{"issue":"3","key":"1046_CR20","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1093\/cid\/ciae321","volume":"79","author":"P Ljungman","year":"2024","unstructured":"Ljungman P, Chemaly RF, Khawaya F, et al. Consensus definitions of cytomegalovirus (CMV) infection and disease in transplant patients including resistant and refractory CMV for use in clinical trials: 2024 update from the Transplant Associated Virus Infections Forum. Clin Infect Dis. 2024;79(3):787\u201394. https:\/\/doi.org\/10.1093\/cid\/ciae321.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"1046_CR21","doi-asserted-by":"publisher","first-page":"5517","DOI":"10.1128\/JCM.42.12.5517-5522.2004","volume":"42","author":"B Musher","year":"2004","unstructured":"Musher B, Fredricks D, Leisenring W, Balajee SA, Smith C, Marr KA. Aspergillus galactomannan enzyme immunoassay and quantitative PCR for diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid. J Clin Microbiol. 2004;42(12):5517\u201322. https:\/\/doi.org\/10.1128\/JCM.42.12.5517-5522.2004.","journal-title":"J Clin Microbiol"},{"issue":"2","key":"1046_CR22","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/cncr.24022","volume":"115","author":"J Maertens","year":"2009","unstructured":"Maertens J, Buve K, Theunissen K, et al. Galactomannan serves as a surrogate endpoint for outcome of pulmonary invasive aspergillosis in neutropenic hematology patients. Cancer. 2009;115(2):355\u201362. https:\/\/doi.org\/10.1002\/cncr.24022.","journal-title":"Cancer"},{"issue":"7","key":"1046_CR23","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1128\/JCM.03567-13","volume":"52","author":"A Sulahian","year":"2014","unstructured":"Sulahian A, Porcher R, Bergeron A, et al. Use and limits of (1\u20133)-beta-d-glucan assay (Fungitell), compared to galactomannan determination (Platelia Aspergillus), for diagnosis of invasive aspergillosis. J Clin Microbiol. 2014;52(7):2328\u201333. https:\/\/doi.org\/10.1128\/JCM.03567-13.","journal-title":"J Clin Microbiol"},{"issue":"2","key":"1046_CR24","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s11046-019-00423-x","volume":"185","author":"MA Mendoza","year":"2020","unstructured":"Mendoza MA, Anderson A, Morris MI, et al. Successful treatment of invasive fungal infection due to highly resistant Aspergillus calidoustus in an allogeneic hematopoietic cell transplant recipient. Mycopathologia. 2020;185(2):399\u2013403. https:\/\/doi.org\/10.1007\/s11046-019-00423-x.","journal-title":"Mycopathologia"},{"issue":"3","key":"1046_CR25","doi-asserted-by":"publisher","first-page":"e0220621","DOI":"10.1128\/aac.02206-21","volume":"66","author":"JF Camargo","year":"2022","unstructured":"Camargo JF, Jabr R, Anderson AD, et al. Successful treatment of disseminated disease due to highly resistant Aspergillus calidoustus with a novel antifungal therapy. Antimicrob Agents Chemother. 2022;66(3):e0220621. https:\/\/doi.org\/10.1128\/aac.02206-21.","journal-title":"Antimicrob Agents Chemother."},{"issue":"6","key":"1046_CR26","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/j.1439-0507.2010.02009.x","volume":"54","author":"SH Park","year":"2011","unstructured":"Park SH, Choi SM, Lee DG, et al. Serum galactomannan strongly correlates with outcome of invasive aspergillosis in acute leukaemia patients. Mycoses. 2011;54(6):523\u201330. https:\/\/doi.org\/10.1111\/j.1439-0507.2010.02009.x.","journal-title":"Mycoses"},{"issue":"7","key":"1046_CR27","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1093\/cid\/cit393","volume":"57","author":"CE Fisher","year":"2013","unstructured":"Fisher CE, Stevens AM, Leisenring W, Pergam SA, Boeckh M, Hohl TM. The serum galactomannan index predicts mortality in hematopoietic stem cell transplant recipients with invasive aspergillosis. Clin Infect Dis. 2013;57(7):1001\u20134. https:\/\/doi.org\/10.1093\/cid\/cit393.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"1046_CR28","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciw326","volume":"63","author":"TF Patterson","year":"2016","unstructured":"Patterson TF, Thompson GR, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1\u201360. https:\/\/doi.org\/10.1093\/cid\/ciw326.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"1046_CR29","doi-asserted-by":"publisher","first-page":"81","DOI":"10.7326\/M13-2508","volume":"162","author":"KA Marr","year":"2015","unstructured":"Marr KA, Schlamm HT, Herbrecht R, et al. Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med. 2015;162(2):81\u20139. https:\/\/doi.org\/10.7326\/M13-2508.","journal-title":"Ann Intern Med"},{"issue":"7","key":"1046_CR30","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1128\/JCM.06513-11","volume":"50","author":"LY Chai","year":"2012","unstructured":"Chai LY, Kullberg BJ, Johnson EM, et al. Early serum galactomannan trend as a predictor of outcome of invasive aspergillosis. J Clin Microbiol. 2012;50(7):2330\u20136. https:\/\/doi.org\/10.1128\/JCM.06513-11.","journal-title":"J Clin Microbiol"},{"issue":"3","key":"1046_CR31","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1080\/10428194.2016.1204652","volume":"58","author":"C Mariette","year":"2017","unstructured":"Mariette C, Tavernier E, Hocquet D, et al. Epidemiology of invasive fungal infections during induction therapy in adults with acute lymphoblastic leukemia: a GRAALL-2005 study. Leuk Lymphoma. 2017;58(3):586\u201393. https:\/\/doi.org\/10.1080\/10428194.2016.1204652.","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"1046_CR32","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1093\/jac\/dkx527","volume":"73","author":"PP Lestrade","year":"2018","unstructured":"Lestrade PP, van der Velden W, Bouwman F, et al. Epidemiology of invasive aspergillosis and triazole-resistant Aspergillus fumigatus in patients with haematological malignancies: a single-centre retrospective cohort study. J Antimicrob Chemother. 2018;73(5):1389\u201394. https:\/\/doi.org\/10.1093\/jac\/dkx527.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"1046_CR33","doi-asserted-by":"publisher","first-page":"e12981","DOI":"10.1111\/tid.12981","volume":"20","author":"S Kuster","year":"2018","unstructured":"Kuster S, Stampf S, Gerber B, et al. Incidence and outcome of invasive fungal diseases after allogeneic hematopoietic stem cell transplantation: a Swiss transplant cohort study. Transpl Infect Dis. 2018;20(6):e12981. https:\/\/doi.org\/10.1111\/tid.12981.","journal-title":"Transpl Infect Dis"},{"issue":"1","key":"1046_CR34","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jinf.2023.05.005","volume":"87","author":"P Puerta-Alcalde","year":"2023","unstructured":"Puerta-Alcalde P, Monzo-Gallo P, Aguilar-Guisado M, et al. Breakthrough invasive fungal infection among patients with haematologic malignancies: a national, prospective, and multicentre study. J Infect. 2023;87(1):46\u201353. https:\/\/doi.org\/10.1016\/j.jinf.2023.05.005.","journal-title":"J Infect"},{"issue":"9","key":"1046_CR35","doi-asserted-by":"publisher","first-page":"4902","DOI":"10.1128\/JCM.43.9.4902-4904.2005","volume":"43","author":"J Pavie","year":"2005","unstructured":"Pavie J, Lacroix C, Hermoso DG, et al. Breakthrough disseminated Aspergillus ustus infection in allogeneic hematopoietic stem cell transplant recipients receiving voriconazole or caspofungin prophylaxis. J Clin Microbiol. 2005;43(9):4902\u20134. https:\/\/doi.org\/10.1128\/JCM.43.9.4902-4904.2005.","journal-title":"J Clin Microbiol"},{"issue":"10","key":"1046_CR36","doi-asserted-by":"publisher","first-page":"3633","DOI":"10.1128\/JCM.01582-14","volume":"52","author":"CE Negri","year":"2014","unstructured":"Negri CE, Goncalves SS, Xafranski H, et al. Cryptic and rare Aspergillus species in Brazil: prevalence in clinical samples and in vitro susceptibility to triazoles. J Clin Microbiol. 2014;52(10):3633\u201340. https:\/\/doi.org\/10.1128\/JCM.01582-14.","journal-title":"J Clin Microbiol"},{"issue":"9","key":"1046_CR37","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1128\/JCM.00962-16","volume":"54","author":"A Masih","year":"2016","unstructured":"Masih A, Singh PK, Kathuria S, Agarwal K, Meis JF, Chowdhary A. Identification by molecular methods and matrix-assisted laser desorption ionization-time of flight mass spectrometry and antifungal susceptibility profiles of clinically significant rare Aspergillus species in a referral chest hospital in Delhi, India. J Clin Microbiol. 2016;54(9):2354\u201364. https:\/\/doi.org\/10.1128\/JCM.00962-16.","journal-title":"J Clin Microbiol"},{"issue":"12","key":"1046_CR38","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1111\/myc.13158","volume":"63","author":"CC Tsang","year":"2020","unstructured":"Tsang CC, Tang JYM, Ye H, et al. Rare\/cryptic Aspergillus species infections and importance of antifungal susceptibility testing. Mycoses. 2020;63(12):1283\u201398. https:\/\/doi.org\/10.1111\/myc.13158.","journal-title":"Mycoses"},{"issue":"8","key":"1046_CR39","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1093\/cid\/ciaa230","volume":"72","author":"E Glampedakis","year":"2021","unstructured":"Glampedakis E, Cassaing S, Fekkar A, et al. Invasive Aspergillosis due to Aspergillus section Usti: a multicenter retrospective study. Clin Infect Dis. 2021;72(8):1379\u201385. https:\/\/doi.org\/10.1093\/cid\/ciaa230.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"1046_CR40","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1093\/cid\/ciad420","volume":"77","author":"J Mah","year":"2023","unstructured":"Mah J, Nicholas V, Tayyar R, et al. Superior accuracy of Aspergillus plasma cell-free DNA polymerase chain reaction over serum galactomannan for the diagnosis of invasive aspergillosis. Clin Infect Dis. 2023;77(9):1282\u201390. https:\/\/doi.org\/10.1093\/cid\/ciad420.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"1046_CR41","doi-asserted-by":"publisher","first-page":"e3876","DOI":"10.1093\/cid\/ciaa1639","volume":"73","author":"JA Hill","year":"2021","unstructured":"Hill JA, Dalai SC, Hong DK, et al. Liquid biopsy for invasive mold infections in hematopoietic cell transplant recipients with pneumonia through next-generation sequencing of microbial cell-free DNA in plasma. Clin Infect Dis. 2021;73(11):e3876\u201383. https:\/\/doi.org\/10.1093\/cid\/ciaa1639.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"1046_CR42","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1093\/infdis\/jiad255","volume":"229","author":"MR Heldman","year":"2024","unstructured":"Heldman MR, Ahmed AA, Liu W, et al. Serial quantitation of plasma microbial cell-free DNA before and after diagnosis of pulmonary invasive mold infections after hematopoietic cell transplant. J Infect Dis. 2024;229(2):576\u201387. https:\/\/doi.org\/10.1093\/infdis\/jiad255.","journal-title":"J Infect Dis"},{"issue":"6","key":"1046_CR43","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.cmi.2016.01.027","volume":"22","author":"S Imbert","year":"2016","unstructured":"Imbert S, Gauthier L, Joly I, et al. Aspergillus PCR in serum for the diagnosis, follow-up and prognosis of invasive aspergillosis in neutropenic and nonneutropenic patients. Clin Microbiol Infect. 2016;22(6):562. https:\/\/doi.org\/10.1016\/j.cmi.2016.01.027.","journal-title":"Clin Microbiol Infect."},{"issue":"10","key":"1046_CR44","doi-asserted-by":"publisher","first-page":"3596","DOI":"10.1128\/JCM.00647-11","volume":"49","author":"L Bernal-Martinez","year":"2011","unstructured":"Bernal-Martinez L, Gago S, Buitrago MJ, Gomez-Lopez A, Rodriguez-Tudela JL, Cuenca-Estrella M. Analysis of performance of a PCR-based assay to detect DNA of Aspergillus fumigatus in whole blood and serum: a comparative study with clinical samples. J Clin Microbiol. 2011;49(10):3596\u20139. https:\/\/doi.org\/10.1128\/JCM.00647-11.","journal-title":"J Clin Microbiol"},{"issue":"3","key":"1046_CR45","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1093\/cid\/ciu833","volume":"60","author":"JM Aguado","year":"2015","unstructured":"Aguado JM, Vazquez L, Fernandez-Ruiz M, et al. Serum galactomannan versus a combination of galactomannan and polymerase chain reaction-based Aspergillus DNA detection for early therapy of invasive aspergillosis in high-risk hematological patients: a randomized controlled trial. Clin Infect Dis. 2015;60(3):405\u201314. https:\/\/doi.org\/10.1093\/cid\/ciu833.","journal-title":"Clin Infect Dis"},{"key":"1046_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/jof6010018","author":"M Egger","year":"2020","unstructured":"Egger M, Jenks JD, Hoenigl M, Prattes J. Blood Aspergillus PCR: the good, the bad, and the ugly. J Fungi. 2020. https:\/\/doi.org\/10.3390\/jof6010018.","journal-title":"J Fungi"},{"issue":"5","key":"1046_CR47","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1093\/mmy\/myw102","volume":"55","author":"S Eigl","year":"2017","unstructured":"Eigl S, Hoenigl M, Spiess B, et al. Galactomannan testing and Aspergillus PCR in same-day bronchoalveolar lavage and blood samples for diagnosis of invasive aspergillosis. Med Mycol. 2017;55(5):528\u201334. https:\/\/doi.org\/10.1093\/mmy\/myw102.","journal-title":"Med Mycol"},{"issue":"10","key":"1046_CR48","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.cmi.2016.06.021","volume":"22","author":"T Boch","year":"2016","unstructured":"Boch T, Spiess B, Cornely OA, et al. Diagnosis of invasive fungal infections in haematological patients by combined use of galactomannan, 1,3-\u03b2-D-glucan, Aspergillus PCR, multifungal DNA-microarray, and Aspergillus azole resistance PCRs in blood and bronchoalveolar lavage samples: results of a prospective multicentre study. Clin Microbiol Infect. 2016;22(10):862\u20138. https:\/\/doi.org\/10.1016\/j.cmi.2016.06.021.","journal-title":"Clin Microbiol Infect"},{"issue":"8","key":"1046_CR49","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.jtct.2022.05.030","volume":"28","author":"J Lindsay","year":"2022","unstructured":"Lindsay J, Krantz EM, Morris J, et al. Voriconazole in hematopoietic stem cell transplantation and cellular therapies: real-world usage and therapeutic level attainment at a Major Transplantation Center. Transplant Cell Ther. 2022;28(8):511. https:\/\/doi.org\/10.1016\/j.jtct.2022.05.030.","journal-title":"Transplant Cell Ther."},{"issue":"5","key":"1046_CR50","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1093\/cid\/ciz282","volume":"70","author":"L Fontana","year":"2020","unstructured":"Fontana L, Perlin DS, Zhao Y, et al. Isavuconazole prophylaxis in patients with hematologic malignancies and hematopoietic cell transplant recipients. Clin Infect Dis. 2020;70(5):723\u201330. https:\/\/doi.org\/10.1093\/cid\/ciz282.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"1046_CR51","doi-asserted-by":"publisher","first-page":"e13469","DOI":"10.1111\/tid.13469","volume":"23","author":"CA Vu","year":"2021","unstructured":"Vu CA, Rana MM, Jacobs SE, Saunders-Hao P. Isavuconazole for the prophylaxis and treatment of invasive fungal disease: a single-center experience. Transpl Infect Dis. 2021;23(2):e13469. https:\/\/doi.org\/10.1111\/tid.13469.","journal-title":"Transpl Infect Dis"},{"issue":"Suppl 1","key":"1046_CR52","doi-asserted-by":"publisher","first-page":"e14162","DOI":"10.1111\/tid.14162","volume":"25","author":"AM Khatri","year":"2023","unstructured":"Khatri AM, Natori Y, Anderson A, et al. Breakthrough invasive fungal infections on isavuconazole prophylaxis in hematologic malignancy & hematopoietic stem cell transplant patients. Transpl Infect Dis. 2023;25(Suppl 1):e14162. https:\/\/doi.org\/10.1111\/tid.14162.","journal-title":"Transpl Infect Dis"},{"issue":"13","key":"1046_CR53","doi-asserted-by":"publisher","first-page":"4358","DOI":"10.1182\/blood-2002-05-1496","volume":"100","author":"KA Marr","year":"2002","unstructured":"Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood. 2002;100(13):4358\u201366. https:\/\/doi.org\/10.1182\/blood-2002-05-1496.","journal-title":"Blood"},{"issue":"4","key":"1046_CR54","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.bbmt.2017.11.038","volume":"24","author":"JF Camargo","year":"2018","unstructured":"Camargo JF, Kimble E, Rosa R, et al. Impact of cytomegalovirus viral load on probability of spontaneous clearance and response to preemptive therapy in allogeneic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2018;24(4):806\u201314. https:\/\/doi.org\/10.1016\/j.bbmt.2017.11.038.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"1046_CR55","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1086\/338624","volume":"185","author":"WG Nichols","year":"2002","unstructured":"Nichols WG, Corey L, Gooley T, Davis C, Boeckh M. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis. 2002;185(3):273\u201382. https:\/\/doi.org\/10.1086\/338624.","journal-title":"J Infect Dis"},{"issue":"20","key":"1046_CR56","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1182\/blood-2015-11-679639","volume":"127","author":"P Teira","year":"2016","unstructured":"Teira P, Battiwalla M, Ramanathan M, et al. Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood. 2016;127(20):2427\u201338. https:\/\/doi.org\/10.1182\/blood-2015-11-679639.","journal-title":"Blood"},{"issue":"7","key":"1046_CR57","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1182\/blood-2013-02-487074","volume":"122","author":"ML Green","year":"2013","unstructured":"Green ML, Leisenring WM, Xie H, et al. CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia. Blood. 2013;122(7):1316\u201324. https:\/\/doi.org\/10.1182\/blood-2013-02-487074.","journal-title":"Blood"},{"issue":"15","key":"1046_CR58","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1007\/s40265-021-01611-0","volume":"81","author":"M Hoenigl","year":"2021","unstructured":"Hoenigl M, Sprute R, Egger M, et al. The antifungal pipeline: fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin. Drugs. 2021;81(15):1703\u201329. https:\/\/doi.org\/10.1007\/s40265-021-01611-0.","journal-title":"Drugs"},{"issue":"6","key":"1046_CR59","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1093\/cid\/ciad309","volume":"77","author":"DJ Winston","year":"2023","unstructured":"Winston DJ, Young PA, Schlamm HT, Schiller GJ. Fosmanogepix therapy of disseminated Fusarium infection. Clin Infect Dis. 2023;77(6):848\u201350. https:\/\/doi.org\/10.1093\/cid\/ciad309.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"1046_CR60","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/S1473-3099(25)00224-5","volume":"25","author":"JA Maertens","year":"2025","unstructured":"Maertens JA, Thompson GR 3rd, Spec A, et al. Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b study. Lancet Infect Dis. 2025;25(11):1177\u201388. https:\/\/doi.org\/10.1016\/S1473-3099(25)00224-5.","journal-title":"Lancet Infect Dis"},{"key":"1046_CR61","doi-asserted-by":"publisher","DOI":"10.3390\/jof10060397","author":"S Yang","year":"2024","unstructured":"Yang S, Wan F, Zhang M, et al. In vitro activitiy of Rezafungin in comparison with Anidulafungin and Caspofungin against invasive fungal isolates (2017\u20132022) in China. J Fungi. 2024. https:\/\/doi.org\/10.3390\/jof10060397.","journal-title":"J Fungi"},{"key":"1046_CR62","doi-asserted-by":"publisher","DOI":"10.3390\/jof9060649","author":"R Vahedi-Shahandashti","year":"2023","unstructured":"Vahedi-Shahandashti R, Houbraken J, Birch M, Lass-Florl C. Novel antifungals and Aspergillus section terrei with potpourri susceptibility profiles to conventional antifungals. J Fungi. 2023. https:\/\/doi.org\/10.3390\/jof9060649.","journal-title":"J Fungi"},{"issue":"11","key":"1046_CR63","doi-asserted-by":"publisher","first-page":"ofae646","DOI":"10.1093\/ofid\/ofae646","volume":"11","author":"SE Jacobs","year":"2024","unstructured":"Jacobs SE, Chaturvedi V. CAF to the rescue! Potential and challenges of combination antifungal therapy for reducing morbidity and mortality in hospitalized patients with serious fungal infections. Open Forum Infect Dis. 2024;11(11):ofae646. https:\/\/doi.org\/10.1093\/ofid\/ofae646.","journal-title":"Open Forum Infect Dis"},{"issue":"9","key":"1046_CR64","doi-asserted-by":"publisher","first-page":"e13544","DOI":"10.1111\/ctr.13544","volume":"33","author":"S Husain","year":"2019","unstructured":"Husain S, Camargo JF. Invasive aspergillosis in solid-organ transplant recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):e13544. https:\/\/doi.org\/10.1111\/ctr.13544.","journal-title":"Clin Transplant"},{"issue":"6","key":"1046_CR65","doi-asserted-by":"publisher","first-page":"ofae133","DOI":"10.1093\/ofid\/ofae133","volume":"11","author":"JS Little","year":"2024","unstructured":"Little JS, Kampouri E, Friedman DZ, et al. The burden of invasive fungal disease following chimeric antigen receptor T-cell therapy and strategies for prevention. Open Forum Infect Dis. 2024;11(6):ofae133. https:\/\/doi.org\/10.1093\/ofid\/ofae133.","journal-title":"Open Forum Infect Dis"},{"issue":"4","key":"1046_CR66","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/bmt.2009.203","volume":"45","author":"VR Shannon","year":"2010","unstructured":"Shannon VR, Andersson BS, Lei X, Champlin RE, Kontoyiannis DP. Utility of early versus late fiberoptic bronchoscopy in the evaluation of new pulmonary infiltrates following hematopoietic stem cell transplantation. Bone Marrow Transplant. 2010;45(4):647\u201355. https:\/\/doi.org\/10.1038\/bmt.2009.203.","journal-title":"Bone Marrow Transplant"}],"container-title":["Mycopathologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11046-025-01046-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11046-025-01046-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11046-025-01046-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T09:07:15Z","timestamp":1777280835000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11046-025-01046-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":66,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1046"],"URL":"https:\/\/doi.org\/10.1007\/s11046-025-01046-1","relation":{},"ISSN":["0301-486X","1573-0832"],"issn-type":[{"value":"0301-486X","type":"print"},{"value":"1573-0832","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"assertion":[{"value":"27 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Institutional Review Board, consistent with principles in the Declaration of Helsinki","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}],"article-number":"29"}}